February 07, 2025

TRANSVAC: a pillar of vaccine development in Europe for 16 years

TRANSVAC: a pillar of vaccine development in Europe for 16 years

The European vaccine development ecosystem has been strengthened over the last 16 years, thanks to the EVI-led TRANSVAC project, an ambitious initiative funded by the European Commission. Since its launch in 2009, TRANSVAC has established itself as a key player in advancing vaccine research, supporting over 160 vaccine projects while fostering innovation and collaboration in the field.

A pioneering infrastructure for vaccine development

A recent article co-authored by experts from 11 leading institutions within the TRANSVAC network highlights its transformative role in supporting vaccine development over the past 16 years. TRANSVAC was designed to create a sustainable vaccine research infrastructure to meet the challenges of developing vaccines for a variety of diseases. The initiative has offered a broad range of services, including preclinical and clinical development support, technology transfer, and specialised training for researchers. By providing access to cutting-edge facilities and expertise, TRANSVAC has to date supported over 160 vaccine projects, aiming to accelerate the vaccine development pipeline by shortening the time between laboratory breakthroughs and clinical application.

Pillars of the TRANSVAC vaccine infrastructure (Martin et al. 2024)

Supporting researchers and industry

The TRANSVAC project has been instrumental in providing researchers and vaccine developers with access to guidance from experts and a broad array of state-of-the-art services that span preclinical and clinical development. Provided services range from antigen characterisation and production to preclinical immunology, vaccine formulation, and support for regulatory procedures and clinical trials. These services have enabled vaccine developers to address critical bottlenecks, ensuring the smooth progression of projects from concept to clinical trials both in academia, SMEs and industry.

Building expertise through training

In addition to providing technical services, TRANSVAC has prioritised capacity building. Through tailored training programs and workshops, the initiative has equipped researchers, clinicians, and technical staff with the skills needed to advance vaccine research and development. This focus on education aims to ensure that Europe remains at the forefront of vaccine innovation, with a highly skilled researchers ready to address emerging health threats. The program is continuing to grow and evolve to meet the changing needs of vaccine developers as the TRANSVAC Academy.

Preparing Europe for future health challenges

While celebrating the significant contributions of TRANSVAC, the article also emphasises the need to adapt to the evolving demands of vaccine research. It highlights key recommendations for future efforts, including enhanced flexibility in service offerings, increased support for pandemic preparedness, and strengthened partnerships between academia and industry. These steps are seen as essential to meet the challenges of emerging infectious diseases and to ensure timely responses to global health emergencies.

Looking ahead, the insights gained from TRANSVAC’s achievements offer a roadmap for strengthening vaccine infrastructure to address future health challenges. By fostering innovation, collaboration, and training, TRANSVAC is well positioned to lead in vaccine innovation and tackle both current and future health challenges.

For further details on TRANSVAC’s impact and achievements, read the full article here.

Our latest News

discover more
Workflow Optimisation in the Laboratory: Premiere of the smartLabs Summit in Heidelberg

Workflow Optimisation in the Laboratory: Premiere of the smartLabs Summit in Heidelberg

On September 24, 2025, the smartLabs Summit will open its doors for the first time in Heidelberg – an event dedicated to practical innovation, digitalization, and automation in laboratories. The Summit will take place at BioLabs Heidelberg (Nicola-Tesla Straße 1–3, 69124 Heidelberg) and offers a full program from 1:00 to 7:30 p.m. Initiated by the […]

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

The aim of the project is to use special quantitative MRI to visualize early changes in the intervertebral disc and enable timely treatment. Ultrashort echo time (UTE) MRI opens up completely new approaches to preventive imaging that are difficult or impossible to achieve with conventional MRI methods. Full text in German below. DFG fördert Heidelberger […]

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Researchers from Heidelberg University’s Medical Faculty, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases (NCT) in Heidelberg have tested the use of targeted drugs in the initial treatment of newly diagnosed glioblastoma, an extremely aggressive brain tumor, in the multicenter study “NCT Neuro Master Match (N2M2)”. Of the five drugs […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp